GO
Loading...

Life Sciences

More

  • *Siemens rises on Egyptian power deals. LONDON/ PARIS, March 16- European stocks rose on Monday and Germany's DAX hit record highs, extending their recent sharp rally as investors bet that the weakened euro would boost the region's economy and lift exporter earnings. The DAX and other European stock markets have been lifted since the start of 2015 by the European...

  • March 9- An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration. The FDA typically accepts the panel's recommendations. The drug is widely expected to win approval by May 13, when the...

  • March 9- CTI BioPharma Corp's experimental blood cancer drug achieved the main goal of a late-stage study, but at least two analysts said the pill would not directly compete with Incyte Corp's treatment. "...we could see pacritinib ultimately finding a niche in the market among low platelet patients and perhaps taking incremental share away from Incyte," Wells...

  • March 9- CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study, sending its shares up 24 percent in premarket trading. CTI BioPharma said nearly 18,000 patients are estimated to live with myelofibrosis in the United States. Pacritinib, one of four cancer compounds CTI BioPharma is developing, is a...

  • March 9- CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study. Data from the study showed that the drug, pacritinib, was significantly better than the "best available therapy" as prescribed by the patients' physician to treat myelofibrosis. Myelofibrosis is a form of blood cancer that makes the bone marrow...

  • *Zarxio from Novartis generics unit Sandoz approved by FDA. *Copy of Amgen's white cell-boosting medicine Neupogen. The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • GENEVA/ LONDON, March 5- Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. All three worst-hit countries- Guinea, Liberia and Sierra Leone- aim to conduct Phase III final-stage clinical trials of experimental vaccines.

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • U.S., Liberia kick off trial of Ebola drug ZMapp Friday, 27 Feb 2015 | 12:50 PM ET

    CHICAGO, Feb 27- U.S. and Liberian researchers have started a clinical trial to test the safety and effectiveness of Mapp Biopharmaceutical Inc's Ebola drug ZMapp, an experimental treatment that has already been tried in a handful of Ebola patients, including two U.S. missionaries. The trial, a joint effort by the Liberian government and the National Institute...

  • Bayer is 'focusing on life sciences'   Thursday, 26 Feb 2015 | 6:00 AM ET
    Bayer is 'focusing on life sciences'

    Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.

  • LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.

  • UMass reverses ban on Iranian science students Wednesday, 18 Feb 2015 | 2:20 PM ET
    UMass Amherst students on campus.

    UMass reversed a controversial policy change and continue to accept Iranian nationals into science and engineering programs, NBC News reports.

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • Feb 10- Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said. Valeant, of Laval, Quebec, will get Seattle- based Dendreon's Provenge cancer treatment and other assets for $400 million in cash. Dendreon and Valeant will seek court...

  • Feb 10- Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process, three sources close to the sale told Reuters. Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge...

  • Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge cancer treatment.

  • LONDON, Feb 1- As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast. Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers...

  • Jan 30- Shares of Spark Therapeutics Inc more than doubled in their debut, valuing the gene-therapy company at nearly $1.5 billion and underscoring investor's interest in the field that recently produced a million-dollar drug. The company's shares opened at $45.10 in their debut on Friday, nearly double their IPO price of $23, and soared to a high of $50 with...

  • Robert Califf, a top cardiologist and researcher, to oversee its drug, medical device and tobacco policy in what experts said is a coup for the FDA. "This is a great catch for the FDA," said Dr. Califf has run countless clinical studies, published more than 1,000 papers, served as an FDA adviser and has twice been interviewed as a potential FDA commissioner.